Literature DB >> 16393885

"Phase I and Phase II" drug metabolism: terminology that we should phase out?

P David Josephy1, F Peter Guengerich, John O Miners.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16393885     DOI： 10.1080/03602530500251220

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


× No keyword cloud information.
  7 in total

Review 1.  Cytochrome P450s and other enzymes in drug metabolism and toxicity.

Authors:  F Peter Guengerich
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 2.  Detoxification reactions: relevance to aging.

Authors:  Piotr Zimniak
Journal:  Ageing Res Rev       Date:  2008-05-02       Impact factor: 10.895

Review 3.  Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review.

Authors:  Lina Schiffer; Lise Barnard; Elizabeth S Baranowski; Lorna C Gilligan; Angela E Taylor; Wiebke Arlt; Cedric H L Shackleton; Karl-Heinz Storbeck
Journal:  J Steroid Biochem Mol Biol       Date:  2019-07-27       Impact factor: 4.292

Review 4.  The safety evaluation of food flavouring substances: the role of metabolic studies.

Authors:  Robert L Smith; Samuel M Cohen; Shoji Fukushima; Nigel J Gooderham; Stephen S Hecht; F Peter Guengerich; Ivonne M C M Rietjens; Maria Bastaki; Christie L Harman; Margaret M McGowen; Sean V Taylor
Journal:  Toxicol Res (Camb)       Date:  2018-03-28       Impact factor: 3.524

Review 5.  The evolving role of drug metabolism in drug discovery and development.

Authors:  Lilian G Yengi; Louis Leung; John Kao
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

6.  An unusually high production of hepatic aflatoxin B1-dihydrodiol, the possible explanation for the high susceptibility of ducks to aflatoxin B1.

Authors:  Gonzalo J Diaz; Hansen W Murcia
Journal:  Sci Rep       Date:  2019-05-29       Impact factor: 4.379

7.  Catalytic approach to in vivo metabolism of atractylenolide III using biomimetic iron-porphyrin complexes.

Authors:  Hanae Lim; Hyeri Jeon; Seungwoo Hong; Jung-Hoon Kim
Journal:  RSC Adv       Date:  2021-10-07       Impact factor: 4.036
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.